Biofrontera (BFRI) Set to Announce Earnings on Friday

Biofrontera (NASDAQ:BFRIGet Rating) is scheduled to post its quarterly earnings results before the market opens on Friday, May 13th. Analysts expect Biofrontera to post earnings of ($0.16) per share for the quarter. Biofrontera has set its FY 2022 guidance at EPS.

Biofrontera (NASDAQ:BFRIGet Rating) last issued its earnings results on Friday, April 8th. The company reported ($0.42) earnings per share for the quarter. The business had revenue of $9.17 million for the quarter. On average, analysts expect Biofrontera to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Shares of Biofrontera stock opened at $3.48 on Friday. Biofrontera has a fifty-two week low of $2.20 and a fifty-two week high of $14.63. The company has a 50 day moving average of $3.38.

Large investors have recently modified their holdings of the company. BlackRock Inc. acquired a new position in shares of Biofrontera during the fourth quarter worth $76,000. Geode Capital Management LLC bought a new position in Biofrontera during the fourth quarter worth $182,000. Finally, Susquehanna International Group LLP bought a new stake in Biofrontera in the fourth quarter valued at $384,000. Institutional investors own 4.10% of the company’s stock.

Separately, Zacks Investment Research lowered shares of Biofrontera from a “buy” rating to a “hold” rating in a research report on Tuesday, March 15th.

Biofrontera Company Profile (Get Rating)

Biofrontera Inc, a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp.

See Also

Receive News & Ratings for Biofrontera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biofrontera and related companies with's FREE daily email newsletter.